Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Hjuler, S
CLINICAL TRIALS WITH CAGRILINTIDE Two clinical trials have investigated the efficacy of cagrilintide in comparison to the GLP-1 agonists liraglutide and semaglutide (Fig
These findings suggest that the observed trend toward benefit is unlikely to be driven by a single biased study, although the overall certainty of evidence remains limited by imprecision and heterogeneity
Overexpression of nuclear receptor subfamily 1, group D member 1 (NR1D1)/Rev-Erba, an orphan nuclear receptor, has been shown to enhance the antimycobacterial properties of macrophages and decrease the survival of M.tb by promoting phagosomelysosome maturation through IL-10 repression in human macrophages[53]
There are also plans to test higher doses starting in the second half of 2026 to see if they can deliver even greater results
